Study S002202

Evaluation of the Clinical and Economic Outcomes Associated With Exenatide Versus Basal Insulin in People With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02987348
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 18000
Start: 2015-06-30
Primary completion: 2015-06-30
Lead sponsor: AstraZeneca
Conditions: Type 2 Diabetes
Interventions: DRUG:exenatide once weekly; DRUG:exenatide twice daily; DRUG:basal insulin
Results posted: FALSE

Registered primary outcomes

Changes from baseline in HbA1c (%) [6, 12 and 24 months]
Changes from baseline in weight (kg) [6, 12 and 24 months]
Changes from baseline in composite outcomes of HbA1c<=7.0% and weight reduction [6, 12 and 24 months]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0026210	Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study. Holden SE, Diabetes, obesity & metabolism	2017	Nonrandomized study	PMID 28218819 DOI	registry reference BACKGROUND:28218819